Lisa G Rider

List of Publications by Year
in descending order

200 papers	15,260 citations	15504 65 h-index	19749 117 g-index
209 all docs	209 docs citations	209 times ranked	9222 citing authors

#	Article	IF	Citations
1	Response to: â€˜Correspondence on â€˜EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsâ€™â€™ by Irfanet al. Annals of the Rheumatic Diseases, 2023, 82, e41-e41.	0.9	1
2	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	5.6	6
3	Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology, 2022, 61, 2969-2977.	1.9	6
4	Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Rheumatology, 2022, 61, SI48-SI55.	1.9	6
5	Association with HLA-DRÎ²1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	2.9	9
6	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	1
7	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine, 2022, 9, 842586.	2.6	2
8	Conflicting reports of antiâ€“cytosolic 5â€²â€nucleotidase <scp>1A</scp> autoantibodies in juvenile dermatomyositis: comment on the article by Rietveld et al. Arthritis and Rheumatology, 2022, 74, 911-912.	5.6	0
9	<scp>47XXY</scp> and <scp>47XXX</scp> in Scleroderma and Myositis. ACR Open Rheumatology, 2022, 4, 528-533.	2.1	8
10	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	1.9	40
11	Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis. Pediatric Rheumatology, 2022, 20, 30.	2.1	5
12	Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. Pediatric Rheumatology, 2022, 20, 28.	2.1	3
13	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	0
14	Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses. Immunity, 2022, 55, 1051-1066.e4.	14.3	13
15	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology, 2021, 60, 1839-1849.	1.9	25
16	Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology, 2021, 60, 2134-2145.	1.9	9
17	Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America. Rheumatology, 2021, 60, 829-836.	1.9	15
18	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2021, 80, 406-408.	0.9	53

#	Article	IF	Citations
19	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. Clinical Rheumatology, 2021, 40, 4095-4100.	2.2	14
20	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	3.8	121
21	Response to: â€˜Comment on: â€˜Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositisâ€™ by Sabbagh Set alâ€™by Yanget al. Annals of the Rheumatic Diseases, 2020, 79, e97-e97.	0.9	0
22	Developing classification criteria for skinâ€predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.5	25
23	Long-term outcomes in Juvenile Myositis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 149-155.	3.4	21
24	Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. Journal of Rheumatology, 2020, 47, 1011-1018.	2.0	17
25	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research, 2020, 72, 1636-1644.	3.4	19
26	The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Research and Therapy, 2020, 22, 117.	3.5	27
27	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2020, 72, 1945-1951.	5.6	28
28	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Scientific Reports, 2020, 10, 4462.	3.3	13
29	Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. Autoimmunity Reviews, 2020, 19, 102533.	5.8	41
30	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Research and Therapy, 2020, 22, 69.	3.5	39
31	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight, 2020, 5, .	5.0	65
32	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	8.2	142
33	Distinguishing Disease Activity and Damage in Myositis. , 2020, , 345-354.		0
34	Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e59-e59.	7.6	58
35	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81
36	Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2019, 78, 988-995.	0.9	99

#	Article	IF	Citations
37	Treatment of calcinosis associated with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. Clinical and Experimental Rheumatology, 2019, 37, 1092-1093.	0.8	3
38	Update on outcome assessment in myositis. Nature Reviews Rheumatology, 2018, 14, 303-318.	8.0	100
39	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2018, 77, 714-719.	0.9	31
40	Medications received by patients with juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 513-522.	3.4	16
41	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.9	36
42	Pediatric Rheumatology Collaborative Study Group â€“ over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatric Rheumatology, 2018, 16, 45.	2.1	35
43	Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology, 2018, 57, 1956-1963.	1.9	24
44	Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatric Rheumatology, 2017, 15, 1.	2.1	65
45	Association of Antiâ€“3â€Hydroxyâ€3â€Methylglutarylâ€Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care and Research, 2017, 69, 1088-1094.	3.4	71
46	Predictors of Reduced Healthâ€Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. Arthritis Care and Research, 2017, 69, 1743-1750.	3.4	32
47	Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. British Journal of Dermatology, 2017, 177, 1086-1092.	1.5	22
48	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology, 2017, 56, 1342-1347.	1.9	46
49	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	5.6	59
50	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
51	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2017, 76, 792-801.	0.9	92
52	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.9	51
53	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.9	754
54	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	3.8	115

#	Article	IF	Citations
55	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	5.6	391
56	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€"methodological aspects. Rheumatology, 2017, 56, 1884-1893.	1.9	33
57	SAT0376â€...ANTI-NT5C1A autoantibodies are frequent in juvenile myositis and associated with increased illness severity. , 2017, , .		0
58	Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology, 2016, 55, kev344.	1.9	41
59	Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis and Rheumatology, 2016, 68, 761-768.	5.6	43
60	CD3Zhypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3Î¶-chain expression in T cells. Rheumatology, 2016, 56, kew405.	1.9	12
61	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. Rheumatology, 2016, 55, 1673-1680.	1.9	11
62	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18â€"20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.6	19
63	The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. Journal of Internal Medicine, 2016, 280, 24-38.	6.0	117
64	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2016, 18, 156.	3.5	4
65	Juvenile Dermatomyositis. , 2016, , 351-383.e18.		22
66	Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. Journal of Rheumatology, 2016, 43, 169-176.	2.0	14
67	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
68	Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2016, 75, 1599-1606.	0.9	36
69	2015 ACR/ARHP Annual Meeting Abstract Supplement. Arthritis and Rheumatology, 2015, 67, 1-4046.	5.6	40
70	Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. Arthritis Research and Therapy, 2015, 17, 238.	3.5	6
71	Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. PLoS ONE, 2015, 10, e0142486.	2.5	16
72	Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?. BMJ Open, 2015, 5, e006636-e006636.	1.9	21

#	Article	IF	Citations
73	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskeletal Disorders, 2015, 16, 257.	1.9	42
74	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes and Immunity, 2015, 16, 470-480.	4.1	103
75	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. Arthritis and Rheumatology, 2014, 66, S86-S87.	5.6	3
76	Confusion Concerning Multiple Versions of the Childhood Myositis Assessment Scale. Arthritis Care and Research, 2014, 66, 648-648.	3.4	5
77	Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Pediatric Rheumatology, 2014, 12, .	2.1	2
78	Myositis registries and biorepositories. Current Opinion in Rheumatology, 2014, 26, 724-741.	4.3	16
79	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S70-S71.	5.6	14
80	Early Illness Features Associated With Mortality in the Juvenile Idiopathic Inflammatory Myopathies. Arthritis Care and Research, 2014, 66, 732-740.	3.4	68
81	The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis. Current Rheumatology Reports, 2014, 16, 467.	4.7	79
82	A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S39-S40.	5.6	1
83	Predictors of Clinical Improvement in Rituximabâ€Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis and Rheumatology, 2014, 66, 740-749.	5.6	210
84	Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskeletal Disorders, 2014, 15, 67.	1.9	18
85	Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clinical and Experimental Rheumatology, 2014, 32, 689-96.	0.8	14
86	P.21.5 Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Neuromuscular Disorders, 2013, 23, 844-845.	0.6	0
87	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
88	Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Journal of the Neurological Sciences, 2013, 333, e458.	0.6	0
89	Developments in the Classification and Treatment of the Juvenile Idiopathic Inflammatory Myopathies. Rheumatic Disease Clinics of North America, 2013, 39, 877-904.	1.9	74
90	Genomeâ€Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113

#	Article	IF	Citations
91	The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (United States), 2013, 92, 223-243.	1.0	224
92	Brief Report: Ultraviolet Radiation Exposure Is Associated With Clinical and Autoantibody Phenotypes in Juvenile Myositis. Arthritis and Rheumatism, 2013, 65, 1934-1941.	6.7	58
93	Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Annals of the Rheumatic Diseases, 2013, 72, 350-356.	0.9	41
94	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.9	109
95	Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy. Arthritis Care and Research, 2013, 65, 1969-1975.	3.4	21
96	The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (United States), 2013, 92, 25-41.	1.0	145
97	Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10RÎ² and IFNAR1 Genes. PLoS ONE, 2013, 8, e67752.	2.5	2
98	THU0241â€...Ethnic but not gender differences in disease manifestations in dermatomyositis patients. Annals of the Rheumatic Diseases, 2013, 71, 236.3-236.	0.9	1
99	Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. American Journal of Human Genetics, 2012, 90, 217-228.	6.2	168
100	Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and Calcinosis. Journal of Pediatrics, 2012, 160, 520-522.	1.8	99
101	Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatology Journal, 2012, 6, 54-63.	0.2	48
102	Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases*. Arthritis Research and Therapy, 2011, 13, R181.	3.5	13
103	Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Research and Therapy, 2011, 13, R69.	3.5	37
104	JUVENILE DERMATOMYOSITIS. , 2011, , 375-413.		16
105	Parents' perception of self-advocacy of children with myositis: an anonymous online survey. Pediatric Rheumatology, 2011, 9, 10.	2.1	8
106	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 929-936.	3.4	391
107	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (Câ€HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SFâ€36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. Arthritis Care and Research, 2011, 63, S118-57.	3.4	288
108	Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies. JAMA - Journal of the American Medical Association, 2011, 305, 183.	7.4	115

#	Article	IF	Citations
109	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care and Research, 2010, 62, 465-472.	3.4	204
110	Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2010, 62, 219-225.	3.4	77
111	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	3.4	84
112	Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: Are current therapies just scratching the surface?. Arthritis and Rheumatism, 2010, 62, 2619-2622.	6.7	3
113	Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology, 2010, 49, 2381-2390.	1.9	44
114	Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Research, 2010, 20, 170-179.	5.5	569
115	Gingival and Periungual Vasculopathy of Juvenile Dermatomyositis. New England Journal of Medicine, 2009, 360, e21.	27.0	30
116	Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology, 2009, 48, 134-139.	1.9	99
117	Metabolic Abnormalities and Cardiovascular Risk Factors in Children with Myositis. Journal of Pediatrics, 2009, 155, 882-887.	1.8	27
118	Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Practice and Research in Clinical Rheumatology, 2009, 23, 665-678.	3.3	102
119	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis and Rheumatism, 2009, 60, 3425-3435.	6.7	107
120	Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2009, 11, R159.	3.5	36
121	On Determining the Effects of Therapy on Disease Damage in Non Randomized Studies with Multiple Treatments: A Study of Juvenile Myositis. Communications in Statistics - Theory and Methods, 2009, 38, 3268-3281.	1.0	0
122	Outcomes and Assessment for Inflammatory Muscle Disease. , 2009, , 253-276.		0
123	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, .	0.5	19
124	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, 1.	0.5	13
125	Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, 2.	0.5	10
126	Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: Results using abbreviated formats. Arthritis and Rheumatism, 2008, 59, 352-356.	6.7	37

#	Article	IF	Citations
127	Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 59, 214-221.	6.7	51
128	Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2008, 58, 3239-3246.	6.7	43
129	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. Arthritis and Rheumatism, 2008, 59, 1197-1198.	6.7	2
130	Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 58, 3941-3950.	6.7	80
131	Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet, The, 2008, 371, 2201-2212.	13.7	383
132	Does early growth hormone therapy prevent glucocorticoid-associated growth retardation in children with JIA?. Nature Clinical Practice Rheumatology, 2008, 4, 394-395.	3.2	1
133	Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. Medicine (United States), 2008, 87, 70-86.	1.0	137
134	Idiopathic Inflammatory Myopathies. , 2008, , 368-374.		45
135	The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology, 2007, 46, 1606-1611.	1.9	48
136	Clinical research networks: a step towards evidence-based practice in pediatric rheumatology. Nature Clinical Practice Rheumatology, 2007, 3, 59-59.	3.2	3
137	Developing international consensus on measures of improvement for patients with myositis. Statistical Methods in Medical Research, 2007, 16, 51-64.	1.5	5
138	Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis and Rheumatism, 2007, 56, 2719-2728.	6.7	55
139	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis and Rheumatism, 2007, 57, 881-884.	6.7	55
140	The heterogeneity of juvenile myositis. Autoimmunity Reviews, 2007, 6, 241-247.	5.8	36
141	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
142	Intra-Rater and Inter-Rater Reliability of the 10-Point Manual Muscle Test (MMT) of Strength in Children with Juvenile Idiopathic Inflammatory Myopathies (JIIM). Physical and Occupational Therapy in Pediatrics, 2006, 26, 5-17.	1.3	24
143	A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis and Rheumatism, 2006, 54, 3682-3689.	6.7	418
144	HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis and Rheumatism, 2006, 54, 3670-3681.	6.7	78

#	Article	IF	Citations
145	Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis and Rheumatism, 2006, 54, 3979-3987.	6.7	66
146	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2006, 85, 111-127.	1.0	140
147	Virus-mediated autoimmunity in Multiple Sclerosis. Journal of Autoimmune Diseases, 2006, 3, 1.	1.0	33
148	Endothelial cell activation and neovascularization are prominent in dermatomyositis. Journal of Autoimmune Diseases, 2006, 3, 2.	1.0	69
149	Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Physical and Occupational Therapy in Pediatrics, 2006, 26, 5-17.	1.3	13
150	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2005, 84, 338-349.	1.0	92
151	Childhood myositis assessment scale and muscle strength testing in patients with juvenile dermatomyositis: Comment on the article by Huber et al. Arthritis and Rheumatism, 2005, 52, 368-368.	6.7	2
152	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2005, 52, 2607-2615.	6.7	146
153	Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2005, 53, 565-570.	6.7	35
154	Parvovirus B19 and Onset of Juvenile Dermatomyositis. JAMA - Journal of the American Medical Association, 2005, 294, 2165.	7.4	29
155	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, 2004, 43, 49-54.	1.9	311
156	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2004, 50, 1595-1603.	6.7	195
157	International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis and Rheumatism, 2004, 50, 2281-2290.	6.7	202
158	Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis and Rheumatism, 2004, 51, 365-370.	6.7	41
159	Walking ability and its relationship to lower extremity muscle strength in children with idiopathic inflammatory myopathies11The opinions expressed in this article reflect the views of the authors and are not necessarily those of the National Institutes of Health and the US Public Health Service.No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the author(s) or on any organization with which the author(s) is/are asso. Archives of Physical Medicine and Rehabilitation, 2004, 85, 767-771.	0.9	22
160	Polymyositis: An overdiagnosed entity. Neurology, 2004, 63, 402-403.	1.1	27
161	Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis and Rheumatism, 2003, 48, 2285-2293.	6.7	167
162	HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis and Rheumatism, 2003, 48, 2567-2572.	6.7	37

#	Article	IF	Citations
163	Diagnostic criteria for polymyositis and dermatomyositis. Lancet, The, 2003, 362, 1762-1763.	13.7	67
164	Fitness as a Determinant of the Oxygen Uptake/Work Rate Slope in Healthy Children and Children With Inflammatory Myopathy. Applied Physiology, Nutrition, and Metabolism, 2003, 28, 888-897.	1.7	21
165	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.3	209
166	Defining Clinical Improvement in Adult and Juvenile Myositis. Journal of Rheumatology, 2003, 30, 603-17.	2.0	124
167	Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheumatic Disease Clinics of North America, 2002, 28, 935-977.	1.9	49
168	Decreased aerobic capacity in children with juvenile dermatomyositis. Arthritis and Rheumatism, 2002, 47, 118-123.	6.7	47
169	Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis and Rheumatism, 2002, 46, 1885-1893.	6.7	86
170	Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clinical Chemistry, 2002, 48, 1681-8.	3.2	31
171	Juvenile dermatomyositis presenting with anasarca: A possible indicator of severe disease activity. Journal of Pediatrics, 2001, 138, 942-945.	1.8	48
172	Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. British Journal of Rheumatology, 2001, 40, 1262-1273.	2.3	270
173	Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology, 2001, 40, 1279-1284.	1.9	55
174	Update on the genetics of the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2000, 12, 482-491.	4.3	86
175	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. Arthritis and Rheumatism, 2000, 43, 1866-1873.	6.7	132
176	Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clinical and Experimental Immunology, 2000, 121, 47-52.	2.6	69
177	Idiopathic inflammatory muscle disease: clinical aspects. Best Practice and Research in Clinical Rheumatology, 2000, 14, 37-54.	3.3	42
178	Postlicensure Safety Surveillance for Varicella Vaccine. JAMA - Journal of the American Medical Association, 2000, 284, 1271.	7.4	182
179	Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Lancet, The, 2000, 356, 2155-2156.	13.7	173
180	Plenary session (ACR). Arthritis and Rheumatism, 2000, 43, S115-S408.	6.7	0

#	Article	IF	Citations
181	Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American Whites: A tale of two loci. Arthritis and Rheumatism, 1999, 42, 1285-1290.	6.7	58
182	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis and Rheumatism, 1999, 42, 2213-2219.	6.7	194
183	Novel gastrointestinal tract manifestations in juvenile dermatomyositis. Journal of Pediatrics, 1999, 135, 371-374.	1.8	42
184	Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis and Rheumatism, 1998, 41, 710-719.	6.7	65
185	Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry. Journal of the American College of Cardiology, 1998, 31, 1658-1666.	2.8	700
186	Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging.. Radiology, 1998, 209, 191-196.	7.3	42
187	CLASSIFICATION AND TREATMENT OF THE JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES. Rheumatic Disease Clinics of North America, 1997, 23, 619-655.	1.9	128
188	The relationship of muscle strength and gait performance in children with juvenile idiopathic inflammatory myopathy. Gait and Posture, 1997, 5, 158-159.	1.4	0
189	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis and Rheumatism, 1997, 40, 1976-1983.	6.7	127
190	Assessment of disease activity and its sequelae in children and adults with myositis. Current Opinion in Rheumatology, 1996, 8, 495-506.	4.3	34
191	Program Overview. Arthritis and Rheumatism, 1996, 39, S27-S325.	6.7	0
192	Myositis: Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy. Annals of Internal Medicine, 1995, 122, 715.	3.9	150
193	Cerebrospinal fluid analysis in children with seizures. Pediatric Emergency Care, 1995, 11, 226-229.	0.9	23
194	A broadened spectrum of juvenile myositis. myositis-specific autoantibodies in children. Arthritis and Rheumatism, 1994, 37, 1534-1538.	6.7	96
195	The cDNAs encoding two forms of the LYN protein tyrosine kinase are expressed in rat mast cells and human myeloid cells. Gene, 1994, 138, 219-222.	2.2	12
196	New perspectives on the idiopathic inflammatory myopathies of childhood. Current Opinion in Rheumatology, 1994, 6, 575-582.	4.3	10
197	Pulmonary hypertension in a seventeen-year-old boy. Journal of Pediatrics, 1992, 120, 149-159.	1.8	13
198	Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. Journal of Pediatrics, 1991, 118, 417-419.	1.8	28

#	Article	IF	Citations
199	Group A streptococcal infection and Kawasaki syndrome. Lancet, The, 1991, 337, 1100-1101.	13.7	9
200	Modes of action of aspirin-like drugs.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7227-7231.	7.1	184